Administration of Indinavir and Low-Dose Ritonavir (800/100 Mg Twice Daily) with Food Reduces Nephrotoxic Peak Plasma Levels of Indinavir

Abstract

Background

The objective of this study was to compare indinavir peak plasma (C_max) values after administration of indinavir/ritonavir 800/100 mg on an empty stomach or with food. High indinavir C_max values have been associated with indinavir-related nephrotoxicity.

Methods

This was an open-label, randomized, two-treatment, two-period, cross-over pharmacokinetic study performed at steady state. HIV-infected patients who had been using indinavir/ritonavir 800/100 mg twice daily for at least 4 weeks were randomized to take this combination with a light breakfast (two filled rolls and 130 ml of fluid) on a first study day, and without food on a second day, or in the reverse order. The pharmacokinetics of indinavir and ritonavir were assessed after plasma and urine sampling during 12 h.

Results

Data for nine patients were evaluated. Administration of indinavir/ritonavir 800/100 mg on an empty stomach resulted in a higher indinavir C_max [geometric mean (GM) ratio – fasting/fed and 95% confidence interval (CI): 1.28 (1.08–1.52), P=0.01] and a trend to a shorter indinavir t_max (P=0.07) compared to administration with food. The mode of administration of indinavir/ritonavir did not affect plasma indinavir C_min and AUC values, parameters that have been associated with the antiviral efficacy of indinavir, nor the urinary excretion of indinavir.

Conclusions

Administration of indinavir/ritonavir 800/100 mg on an empty stomach results in a higher indinavir C_max compared to ingestion with a light meal. Stated the other way round, intake with a light meal reduces indinavir C_max, which probably reflects a food-induced delay in the absorption of indinavir. It is recommended to administer indinavir/ritonavir 800/100 mg with food, as a possible means to prevent indinavir-related nephrotoxicity in patients who start or continue with this regimen.